Stockscreener 앱 받기
3.11
0.65%
0.02
전일 마감가:
$3.09
열려 있는:
$3.06
하루 거래량:
16,111
Relative Volume:
0.39
시가총액:
$17.27M
수익:
-
순이익/손실:
$-16.35M
주가수익비율:
-1.0197
EPS:
-3.05
순현금흐름:
$-11.88M
1주 성능:
-5.18%
1개월 성능:
+22.92%
6개월 성능:
-2.81%
1년 성능:
-36.66%
1일 변동 폭
$2.98
$3.149
1주일 범위
$2.98
$3.4499
52주 변동 폭
$2.52
$5.50
Lipocine Inc Stock (LPCN) Company Profile
명칭
Lipocine Inc
전화
801 994 7383
주소
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
LPCN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.11 | 17.16M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-06-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-10 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | 재확인 | H.C. Wainwright | Buy |
| 2018-01-11 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | 재개 | H.C. Wainwright | Buy |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2015-07-22 | 개시 | ROTH Capital | Buy |
| 2015-06-23 | 개시 | Canaccord Genuity | Buy |
모두보기
Lipocine Inc 주식(LPCN)의 최신 뉴스
Lipocine Inc. (LPCN) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Lipocine reports ‘promising’ safety profile in Phase 3 trial of LPCN 1154 - MSN
Why hedge funds are buying Lipocine Inc. stockPortfolio Profit Report & Precise Trade Entry Recommendations - newser.com
Can Lipocine Inc. stock sustain revenue growthJuly 2025 Weekly Recap & Community Consensus Stock Picks - newser.com
Will Lipocine Inc. stock outperform value stocksMarket Risk Report & Low Risk High Win Rate Stock Picks - newser.com
Can Lipocine Inc. stock resist sector downturnsJuly 2025 Recap & AI Powered Market Trend Analysis - newser.com
How Lipocine Inc. stock reacts to inflationary pressuresOptions Play & Free Growth Oriented Trading Recommendations - newser.com
Smart tools for monitoring Lipocine Inc.’s price actionEarnings Summary Report & Community Driven Trade Alerts - newser.com
Is Lipocine Inc. stock a safe buy before earningsQuarterly Portfolio Summary & Daily Stock Trend Watchlist - newser.com
Lipocine reports positive safety review for PPD treatment in phase 3 trial - Investing.com Nigeria
Lipocine Announces Positive Interim Results for PPD Trial - TipRanks
[8-K] Lipocine Inc. Reports Material Event | LPCN SEC FilingForm 8-K - Stock Titan
Lipocine highlights promising interim safety profile in phase 3 trial of LPCN 1154 in postpartum depression (PPD) - MarketScreener
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - The Herald Journal
HC Wainwright Issues Negative Forecast for Lipocine Earnings - Defense World
Will Lipocine Inc. stock go up soonForecast Cut & Long-Term Growth Plans - newser.com
HC Wainwright Cuts Lipocine (NASDAQ:LPCN) Price Target to $7.00 - Defense World
Why analysts upgrade Lipocine Inc. stockJuly 2025 Earnings & Entry and Exit Point Strategies - newser.com
Lipocine price target lowered to $7 from $8 at H.C. Wainwright - MSN
How Lipocine Inc. stock performs after earningsDollar Strength & Growth Oriented Trade Recommendations - newser.com
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline - Investing.com Nigeria
Lipocine stock price target lowered to $7 at H.C. Wainwright on PPD trial timeline By Investing.com - Investing.com South Africa
LPCN: Analyst Lowers Price Target While Maintaining Buy Rating | - GuruFocus
Will a bounce in Lipocine Inc. offer an exitEarnings Risk Report & Weekly Watchlist for Consistent Profits - newser.com
Lipocine Inc (LPCN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):